Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients

Maurizio Coppola, MD; Raffaella Mondola, MD

doi:10.5055/jom.2020.0564

Authors

Maurizio Coppola, MD
Raffaella Mondola, MD

DOI:

https://doi.org/10.5055/jom.2020.0564

Abstract

-

Author Biographies

Maurizio Coppola, MD

Medical Manager, Department of Addiction, Alba (CN), Italy

Raffaella Mondola, MD

Medical Manager, Department of Mental Health, Saluzzo (CN), Italy

References

Chan JF, Kok KH, Zhu Z, et al: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9: 231-236.

American Society of Addiction Medicine: Covid-19 resources 2020. Available at: https://www.asam.org/Quality-Science/covid-19-coronavirus Accessed April 2, 2020.

Adem S, Eyupoglu V, Sarfraz I, et al.: Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: An in silico strategy unveils a hope against corona. Preprints. 2020; doi: 10.20944/preprints202003.0333.v1

Loscalzo LM, Wasowski C, Paladini AC, et al.: Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines. Eur J Pharmacol. 2008; 580: 306-313.

Selvaraj G, Kaliamurthi S, Thirungnasambandam R, et al.: Antinociceptive effect in mice of thillai flavonoid rutin. Biomed Environ Sci. 2014; 27: 295-299.